Valvular & structural heart diseaseSecondary analysis
Impact of renin–angiotensin system inhibitors on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis of from the PARTNER 2 trial and registries
- Secondary analysis of the PARTNER 2 trial and registries
- study-stratified multivariable Cox regression
- propensity score matching sensitivity analysis
Authors' conclusion
In a large cohort of patients with severe symptomatic AS from the PARTNER 2 trial and registries, ACEI/ARB treatment at baseline was independently associated with a lower risk of 2-year all-cause and cardiovascular mortality.
Study context
- Population
- Intermediate, high or prohibitive risk patients with symptomatic severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) (excluding valve-in-valve registry)
- Participants
- 3,979 participants
- Comparison
- ACEI/ARB treatment at baseline vs no ACEI/ARB
- ACEI/ARBn = 1,736
- No ACEI/ARBn = 2,243reference
- Primary endpoint
- All-cause mortality
- Follow-up
- 2 years
Primary result
As reported in the abstract
P < 0.0001
Further findings
CV mortality · 2 years
P < 0.0001
Non-CV mortality · 2 years
P < 0.0001
Original publication
Impact of renin–angiotensin system inhibitors on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis of from the PARTNER 2 trial and registries. Eur Heart J. Published 11 November 2019. doi:10.1093/eurheartj/ehz769
Summarised from the published abstract; every number is checked against it